Research, editing : Gan Yung Chyan, KUCINTA SETIA
News on disease control, Taiwan
News (1) to (2) / Reporter : Wu Jiayu / news.tvbs.com.tw/life/1716134
News (1)
Medigen vaccine MVC-COV1901 recognized by 8 countries, Taiwan plans to plan vaccine humanitarian rescue
Image : Web Screenshot
Medigen's covi vaccine MVC-COV1901 vaccine received an EUA from the Paraguayan government on 14 February 2022. Chen Shizhong, commander of the command centre, said on 15 February 2022 that a total of 8 countries in the world have recognized MVC-COV1901, and Taiwan's remaining 3 million doses will be planned for humanitarian relief in addition to domestic use.
The covid pandemic is spreading. Good news came from Medigen on 14 February. MVC-COV1901 reached the clinical unblindness standard in Paraguay’s Phase III vaccine and obtained the Emergency Use Authorization (EUA) approved by Paraguay.
Chen Shizhong said at the press conference this afternoon that this Medigen EUA in Paraguay adopts the same immune bridging method as Taiwan, and the experimental results are also similar to those in Taiwan, which means that the vaccine is different.
In national trials, high consistency can be maintained, and it is believed that it will be recognized by more countries in the future. Chen Shizhong said that according to the Ministry of Foreign Affairs, a total of 8 countries in the world have recognized MVC COVID-19 Vaccine, including Indonesia, Palau, New Zealand, Belize, Somaliland, Estonia, Thailand and Paraguay.
Chen Shizhong also pointed out that up to now, more than 1.922 million doses of MVC-COV1901 have been administered on people in the Republic of China, with about 831,000 doses of the first dose, about 739,000 doses of the second dose, about 341,000 doses of the third dose, and about 9,700 doses of the basic booster.
Chen Shizhong said that Taiwan had previously signed with Medigen to purchase this batch of about 5 million doses. After deducting the nearly 2 million doses that have been used, the government currently has 3 million doses. On the one hand, it is provided for domestic use and the remainder for humanitarian rescue. (Central News Agency)
News (2)
As WHO solidarity trial vaccine Medigen has high chance to unblind by early April 2022
Medigen's covi vaccine MVC-COV1901 has been approved by Paraguay for Emergency Use Authorization (EUA). Chen Canjian, General Manager of Medigen, said today that in addition to the EUA in Paraguay, the WHO solidarity trial vaccine has the opportunity to unravel the blindness at the end of March and early April, and Medigen has prepared hundreds of millions of dollars. The goal is to move from domestic vaccines to international vaccines.
Medigen held a press conference to obtain the EUA of the Paraguay vaccine this afternoon. Chen Canjian said that in addition to the clinical unblinding of the Paraguay Phase III vaccine, the follow-up WHO Solidarity Trial Vaccines is currently in progress as scheduled. If the condition of the tester is diagnosed, the mid-term unblinding can be carried out, and it is estimated that there will be results at the end of March and early April. (Central News Agency)
News (3)
MVC-COV1901 phase III unblinding results released Paraguay simultaneously "approved EUA"
Reporter : Lai Huijin / news.tvbs.com.tw/life/1715692
Medigen on 14 February 2022 announced the unblinding results of the Phase III clinical trial of the MVC COVID-19 vaccine (MVC-COV1901) in Paraguay. The data showed that the vaccine was safe and well tolerated, and the neutralizing antibody titer was 3.7 times that of the control group AZ vaccine, setting a superiority benchmark through the trial (superiority), and Paraguay simultaneously approved the EUA emergency authorization.
Medigen issued a press release on 14 February stating that the third phase of the trial in Paraguay has reached the benchmark of superiority. In response to local epidemic prevention needs, DINAVISA, the competent authority for pharmaceutical regulations in Paraguay, is completing on-site plant inspections and reviewing relevant drug toxicology and animal tests. After the first and second phase clinical trials in Taiwan, as well as technical documents such as the third phase clinical trial in Paraguay and chemical manufacturing control, the emergency use authorization (EUA) of MVC-COV1901 in Paraguay is approved on 14 February 2022. (Central News Agency)
No comments:
Post a Comment